Skip to content

Biosimilars news

Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.

A legislative update on provincial biosimilar policies

This Benefits Canada article highlights how private insurers can benefit from aligning with provincial biosimilars policies.

Read more

How plan sponsors can contain rising drug costs in 2021

This Benefits Canada article highlights the importance of maximizing the use of biosimilar and generic medicines to ensure plan sustainability. 

Read more

IGBA Launches First Global Biosimilars Week

Biosimilars Canada is participating in this globally aligned educational initiative to raise awareness of biosimilar medicines from November 16 to 20.

Read more

New study by the Ontario Drug Policy Research Network

A new study by the Ontario Drug Policy Research Network found that provinces could save up to $426 million by implementing biosimilar switching policies.

Read more

Favouring generics and biosimilars to reduce the bill for group benefit plans

Op-ed in Advantages magazine by Jim Keon, President of the Canadian Generic Pharmaceutical Association and its Biosimilars Canada division, which highlights the benefits of expanding the use of generic and biosimilar medicines for group drug benefit plans. Available in French only.

Read more

Alberta switching Rituxan rituximab patients to biosimilars

Alberta is expanding its biosimilars program by switching Rituxan rituximab patients to biosimilars. The Province has also added coverage for three new biosimilars.

Read more